The drostanolone propionate-treated animals show a marked weight increase caused by the anabolic effect of the compound. The difference growing in the course of the experiment between gross body weight and net body weight can be interpreted as the actual increase of weight of the tumors. The increase of gross body weight in the group treated with the combination corresponds to that of the group treated with drostanolone propionate alone.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Treatment of Advanced Breast Carcinoma with Drostanolone Propionate A Case Report
N. M. Heney, et al, Bristol Med Chir J. 1970 Jul;85(3): 75–76.
|2-Chloro-5- nitro-benzeneacetic acid|
FX1 is a potent and specific BCL6 inhibitor, with an IC50 of around 35 μM.
GC376 is a 3CLpro inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM.
AVex-73 hydrochloride is a Sigma-1 Receptor agonist with an IC50 of 860 nM.
Tropifexor is a novel and highly potent agonist of farnesoid X receptor (FXR).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.